medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2017, Number 3

<< Back Next >>

Ann Hepatol 2017; 16 (3)

Testosterone, Sex Hormone-Binding Globulin and Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis

Jaruvongvanich V, Sanguankeo A, Riangwiwat T, Upala S

Language: English
References: 60
Page: 382-394
PDF size: 194.48 Kb.


ABSTRACT

Introduction and aim. Endogenous sex hormones are associated with the risk of diabetes and metabolic syndrome. Recent studies suggested the role of these hormones in nonalcoholic fatty liver disease (NAFLD). We conducted a systematic review and meta-analysis of observational studies investigating the association between sex hormones and NAFLD. Material and methods. A comprehensive search of the databases of the MEDLINE and EMBASE was performed from inception through April 2016. The inclusion criterion was the observational studies that assessed the association of serum total testosterone (TT) and sex-hormone binding globulin (SHBG) and NAFLD. We calculated pooled effect estimates of TT and SHBG with 95% confidence intervals (CI) comparing between subjects with and without NAFLD by using random-effects model. Results. Sixteen trials comprising 13,721 men and 5,840 women met the inclusion criteria. TT levels were lower in men with NAFLD (MD = -2.78 nmol/l, 95%CI -3.40 to -2.15, I2 = 99%) than in those without. Men with higher TT levels had lower odds of NAFLD whereas higher TT levels increased the odds of NAFLD in women. In both sexes, SHBG levels were lower in patients with NAFLD than controls and this inverse association was stronger in women than men and higher SHBG levels were associated with reduced odds of NAFLD. Conclusion. Our meta-analysis demonstrated a sex-dependent association between TT and NAFLD. Lower TT levels are associated with men with NAFLD and inversely associated with women with NAFLD, whereas higher SHBG levels are associated with lower NAFLD odds in both men and women.


REFERENCES

  1. Angulo P. Nonalcoholic fatty liver disease. New Engl J 2002; 346: 1221-31.

  2. Rinella ME. Nonalcoholic fatty liver disease: a systematic review. JAMA 2015; 313: 2263-73.

  3. Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Alimentary pharmacology & therapeutics 2011; 34: 274-85.

  4. Jaruvongvanich V, Sanguankeo A, Upala S. Significant Association Between Gallstone Disease and Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. Digestive Diseases And Sciences 2016.

  5. Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, Natale S, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003; 37: 917-23.

  6. Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. New Engl J 2010; 363: 1341-50.

  7. van der Poorten D, Milner KL, Hui J, Hodge A, Trenell MI, Kench JG, London R, et al. Visceral fat: a key mediator of steatohepatitis in metabolic liver disease. Hepatology 2008; 48: 449-57.

  8. Endre T, Mattiasson I, Berglund G, Hulthen UL. Low testosterone and insulin resistance in hypertension-prone men. J Human Hypertension 1996; 10: 755-61.

  9. Oh JY, Barrett-Connor E, Wedick NM, Wingard DL, Rancho Bernardo S. Endogenous sex hormones and the development of type 2 diabetes in older men and women: the Rancho Bernardo study. Diab Car 2002; 25: 55-60.

  10. Pitteloud N, Mootha VK, Dwyer AA, Hardin M, Lee H, Eriksson KF, Tripathy D, et al. Relationship between testosterone levels, insulin sensitivity, and mitochondrial function in men. Diab Car 2005; 28: 1636-42.

  11. Kelly DM, Jones TH. Testosterone and obesity. Obesity Reviews 2015; 16: 581-606.

  12. Tok EC, Ertunc D, Evruke C, Dilek S. The androgenic profile of women with non-insulin-dependent diabetes mellitus. The Journal of reproductive medicine 2004; 49: 746-52.

  13. Toprak S, Yonem A, Cakir B, Guler S, Azal O, Ozata M, Corakci A. Insulin resistance in nonobese patients with polycystic ovary syndrome. Hormone Research 2001; 55: 65-70.

  14. Kalish GM, Barrett-Connor E, Laughlin GA, Gulanski BI. Postmenopausal Estrogen/Progestin Intervention T. Association of endogenous sex hormones and insulin resistance among postmenopausal women: results from the Postmenopausal Estrogen/Progestin Intervention Trial. The Journal Of Clinical Endocrinology And Metabolism 2003; 88: 1646-52.

  15. Andersson B, Marin P, Lissner L, Vermeulen A, Bjorntorp P. Testosterone concentrations in women and men with NIDDM. Diab Car 1994; 17: 405-11.

  16. Pugeat M, Nader N, Hogeveen K, Raverot G, Dechaud H, Grenot C. Sex hormone-binding globulin gene expression in the liver: drugs and the metabolic syndrome. Molecular and cellular Endocrinology 2010; 316: 53-9.

  17. Simo R, Saez-Lopez C, Barbosa-Desongles A, Hernandez C, Selva DM. Novel insights in SHBG regulation and clinical implications. TEM 2015; 26: 376-83.

  18. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000; 283: 2008-12.

  19. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 2010; 25: 603-5.

  20. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557-60.

  21. Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Medical Research Methodology 2005; 5: 13.

  22. Sterne JA, Egger M. Funnel plots for detecting bias in metaanalysis: guidelines on choice of axis. Journal Of Clinical Epidemiology 2001; 54: 1046-55.

  23. Ayonrinde OT, Adams LA, Doherty DA, Mori TA, Beilin LJ, Oddy WH, Hickey M, et al. Adverse metabolic phenotype of adolescent girls with non-alcoholic fatty liver disease plus polycystic ovary syndrome compared with other girls and boys. J Gastroenter Hepatol 2016; 31: 980-7.

  24. Barbonetti A, Caterina Vassallo MR, Cotugno M, Felzani G, Francavilla S, Francavilla F. Low testosterone and non-alcoholic fatty liver disease: Evidence for their independent association in men with chronic spinal cord injury. The Journal Of Spinal Cord Medicine 2016: 1-7.

  25. Corbould A, Bhathal PS, Dixon JB, O’Brien PE. Interrelationships of serum androgens, omental adipose tissue metabolism, and nonalcoholic fatty liver disease in obese premenopausal women. Metabolic syndrome and related disorders 2014; 12: 311-9.

  26. Flechtner-Mors M, Schick A, Oeztuerk S, Haenle MM, Wilhelm M, Koenig W, Imhof A, et al. Associations of fatty liver disease and other factors affecting serum SHBG concentrations: a population based study on 1657 subjects. Hormone and metabolic research [Hormon- und Stoffwechselforschung = Hormones et metabolisme] 2014; 46: 287-93.

  27. Kauffman RP, Baker TE, Baker V, Kauffman MM, Castracane VD. Endocrine factors associated with non-alcoholic fatty liver disease in women with polycystic ovary syndrome: do androgens play a role? Gynecological Endocrinology 2010; 26: 39-46.

  28. Kim S, Kwon H, Park JH, Cho B, Kim D, Oh SW, Lee CM, et al. A low level of serum total testosterone is independently associated with nonalcoholic fatty liver disease. BMC Gastroenterology 2012; 12: 69.

  29. Lazo M, Zeb I, Nasir K, Tracy RP, Budoff MJ, Ouyang P, Vaidya D. Association Between Endogenous Sex Hormones and Liver Fat in a Multiethnic Study of Atherosclerosis. Clin Gastroenterol Hepatol 2015; 13: 1686-93 e2.

  30. Li Y, Liu L, Wang B, Chen D, Wang J. Nonalcoholic fatty liver disease and alteration in semen quality and reproductive hormones. Eur J Gastroenterol Hepatol 2015; 27: 1069-73.

  31. Seo NK, Koo HS, Haam JH, Kim HY, Kim MJ, Park KC, Park KS, et al. Prediction of prevalent but not incident non-alcoholic fatty liver disease by levels of serum testosterone. J Gastroenterol Hepatol 2015; 30: 1211-6.

  32. Shin JY, Kim SK, Lee MY, Kim HS, Ye BI, Shin YG, Baik SK, et al. Serum sex hormone-binding globulin levels are independently associated with nonalcoholic fatty liver disease in people with type 2 diabetes. Diab Research Clin Pract 2011; 94: 156-62.

  33. Tian GX, Sun Y, Pang CJ, Tan AH, Gao Y, Zhang HY, Yang XB, et al. Oestradiol is a protective factor for non-alcoholic fatty liver disease in healthy men. Obesity reviews 2012; 13: 381-7.

  34. Volzke H, Aumann N, Krebs A, Nauck M, Steveling A, Lerch MM, Rosskopf D, et al. Hepatic steatosis is associated with low serum testosterone and high serum DHEAS levels in men. Int J Androl 2010; 33: 45-53.

  35. Wang N, Zhai H, Zhu C, Li Q, Han B, Chen Y, Zhu C, et al. Combined Association of Vitamin D and Sex Hormone Binding Globulin With Nonalcoholic Fatty Liver Disease in Men and Postmenopausal Women: A Cross-Sectional Study. Medicine 2016; 95: e2621.

  36. Hua X, Sun Y, Zhong Y, Feng W, Huang H, Wang W, Zhang T, et al. Low serum sex hormone-binding globulin is associated with nonalcoholic fatty liver disease in type 2 diabetic patients. Clin Endocrinol 2014; 80: 877-83.

  37. Polyzos SA, Kountouras J, Tsatsoulis A, Zafeiriadou E, Katsiki E, Patsiaoura K, Zavos C, et al. Sex steroids and sex hormone-binding globulin in postmenopausal women with nonalcoholic fatty liver disease. Hormones 2013; 12: 405- 16.

  38. Vassilatou E, Lafoyianni S, Vryonidou A, Ioannidis D, Kosma L, Katsoulis K, Papavassiliou E, et al. Increased androgen bioavailability is associated with non-alcoholic fatty liver disease in women with polycystic ovary syndrome. Human reproduction 2010; 25: 212-20.

  39. Brand JS, van der Tweel I, Grobbee DE, Emmelot-Vonk MH, van der Schouw YT. Testosterone, sex hormone-binding globulin and the metabolic syndrome: a systematic review and meta-analysis of observational studies. Int J Epidemiol 2011; 40: 189-207.

  40. Ding EL, Song Y, Malik VS, Liu S. Sex differences of endogenous sex hormones and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA 2006; 295: 1288-99.

  41. Cohen PG. The hypogonadal-obesity cycle: role of aromatase in modulating the testosterone-estradiol shunt—a major factor in the genesis of morbid obesity. Medical Hypotheses 1999; 52: 49-51.

  42. Rao PM, Kelly DM, Jones TH. Testosterone and insulin resistance in the metabolic syndrome and T2DM in men. Nat Rev Endocrinol 2013; 9: 479-93.

  43. Mirza MS. Obesity, Visceral Fat, and NAFLD: Querying the Role of Adipokines in the Progression of Nonalcoholic Fatty Liver Disease. ISRN Gastroenterology 2011; 2011: 592404.

  44. van der Poll T, Romijn JA, Endert E, Sauerwein HP. Effects of tumor necrosis factor on the hypothalamic-pituitary-testicular axis in healthy men. Metabolism 1993; 42: 303-7.

  45. Tsigos C, Papanicolaou DA, Kyrou I, Raptis SA, Chrousos GP. Dose-dependent effects of recombinant human interleukin- 6 on the pituitary-testicular axis. Journal Of Interferon & Cytokine Research 1999; 19: 1271-6.

  46. Phillips GB, Jing T, Heymsfield SB. Does insulin resistance, visceral adiposity, or a sex hormone alteration underlie the metabolic syndrome? Studies in women. Metabolism 2008; 57: 838-44.

  47. Liu Y, Ding J, Bush TL, Longenecker JC, Nieto FJ, Golden SH, Szklo M. Relative androgen excess and increased cardiovascular risk after menopause: a hypothesized relation. Am J Epidemiology 2001; 154: 489-94.

  48. Rando G, Wahli W. Sex differences in nuclear receptor-regulated liver metabolic pathways. Biochimica et biophysica acta 2011; 1812: 964-73.

  49. Peterson MP, Rosvall KA, Taylor CA, Lopez JA, Choi JH, Ziegenfus C, Tang H, et al. Potential for sexual conflict assessed via testosterone-mediated transcriptional changes in liver and muscle of a songbird. J Experimental Biol 2014; 217: 507-17.

  50. Stojsavljevic S, Gomercic Palcic M, Virovic Jukic L, Smircic Duvnjak L, Duvnjak M. Adipokines and proinflammatory cytokines, the key mediators in the pathogenesis of nonalcoholic fatty liver disease. World J Gastroenterol 2014; 20: 18070-91.

  51. Corona G, Monami M, Rastrelli G, Aversa A, Tishova Y, Saad F, Lenzi A, et al. Testosterone and metabolic syndrome: a meta-analysis study. The Journal Of Sexual Medicine 2011; 8: 272-83.

  52. Hoyos CM, Yee BJ, Phillips CL, Machan EA, Grunstein RR, Liu PY. Body compositional and cardiometabolic effects of testosterone therapy in obese men with severe obstructive sleep apnoea: a randomised placebo-controlled trial. European Journal Of Endocrinology / European Federation Of Endocrine Societies 2012; 167: 531-41.

  53. Huang G, Bhasin S, Tang ER, Aakil A, Anderson SW, Jara H, Davda M, et al. Effect of testosterone administration on liver fat in older men with mobility limitation: results from a randomized controlled trial. The Journals Of Gerontology Series A, Biological Sciences And Medical Sciences 2013; 68: 954-9.

  54. Basaria S, Coviello AD, Travison TG, Storer TW, Farwell WR, Jette AM, Eder R, et al. Adverse events associated with testosterone administration. N Engl J 2010; 363: 109-22.

  55. Kosaka A, Takahashi H, Yajima Y, Tanaka M, Okamura K, Mizumoto R, Katsuta K. Hepatocellular carcinoma associated with anabolic steroid therapy: report of a case and review of the Japanese literature. J Gastroenterol 1996; 31: 450-4.

  56. Socas L, Zumbado M, Perez-Luzardo O, Ramos A, Perez C, Hernandez JR, Boada LD. Hepatocellular adenomas associated with anabolic androgenic steroid abuse in bodybuilders: a report of two cases and a review of the literature. Brit J Sports Med 2005; 39: e27.

  57. Solbach P, Potthoff A, Raatschen HJ, Soudah B, Lehmann U, Schneider A, Gebel MJ, et al. Testosterone-receptor positive hepatocellular carcinoma in a 29-year old bodybuilder with a history of anabolic androgenic steroid abuse: a case report. BMC Gastroenterology 2015; 15: 60.

  58. Xu L, Freeman G, Cowling BJ, Schooling CM. Testosterone therapy and cardiovascular events among men: a systematic review and meta-analysis of placebo-controlled randomized trials. BMC Medicine 2013; 11: 108.

  59. Lee SS, Park SH. Radiologic evaluation of nonalcoholic fatty liver disease. World J Gastroenterol 2014; 20: 7392-402.

  60. Hernaez R, Lazo M, Bonekamp S, Kamel I, Brancati FL, Guallar E, Clark JM. Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis. Hepatology 2011; 54: 1082-90.




2020     |     www.medigraphic.com